These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

161 related items for PubMed ID: 6175178

  • 1. Plasma accumulation of metabolism of orally administered single dose L-5-hydroxytryptophan in man.
    Magnussen I, Jensen TS, Rand JH, Van Woert MH.
    Acta Pharmacol Toxicol (Copenh); 1981 Sep; 49(3):184-9. PubMed ID: 6175178
    [Abstract] [Full Text] [Related]

  • 2. L-5-hydroxytryptophan. Correlation between anticonvulsant effect and increases in levels of 5-hydroxyindoles in plasma and brain.
    Löscher W, Pagliusi SR, Müller F.
    Neuropharmacology; 1984 Sep; 23(9):1041-8. PubMed ID: 6083501
    [Abstract] [Full Text] [Related]

  • 3. Kinetics of l-5-hydroxytryptophan in healthy subjects.
    Westenberg HG, Gerritsen TW, Meijer BA, van Praag HM.
    Psychiatry Res; 1982 Dec; 7(3):373-85. PubMed ID: 6187038
    [Abstract] [Full Text] [Related]

  • 4. The effects of aromatic amino acid decarboxylase inhibitors on plasma concentrations of 5-hydroxytryptophan in man.
    Magnussen I, Engbaek F.
    Acta Pharmacol Toxicol (Copenh); 1978 Jul; 43(1):36-42. PubMed ID: 309271
    [Abstract] [Full Text] [Related]

  • 5. The effect of oral 5-HTP administration on 5-HTP and 5-HT immunoreactivity in monoaminergic brain regions of rats.
    Lynn-Bullock CP, Welshhans K, Pallas SL, Katz PS.
    J Chem Neuroanat; 2004 May; 27(2):129-38. PubMed ID: 15121217
    [Abstract] [Full Text] [Related]

  • 6. Effects of carbidopa on the cerebral accumulation of exogenous L-5-hydroxytryptophan in mice.
    Magnussen I.
    Acta Pharmacol Toxicol (Copenh); 1984 Sep; 55(3):199-202. PubMed ID: 6334429
    [Abstract] [Full Text] [Related]

  • 7. Central and peripheral mechanisms contribute to the antiemetic actions of delta-9-tetrahydrocannabinol against 5-hydroxytryptophan-induced emesis.
    Darmani NA, Johnson JC.
    Eur J Pharmacol; 2004 Mar 19; 488(1-3):201-12. PubMed ID: 15044052
    [Abstract] [Full Text] [Related]

  • 8. Pharmacology of rising oral doses of 5-hydroxytryptophan with carbidopa.
    Smarius LJ, Jacobs GE, Hoeberechts-Lefrandt DH, de Kam ML, van der Post JP, de Rijk R, van Pelt J, Schoemaker RC, Zitman FG, van Gerven JM, Gijsman HJ.
    J Psychopharmacol; 2008 Jun 19; 22(4):426-33. PubMed ID: 18308795
    [Abstract] [Full Text] [Related]

  • 9. Serum levels of 5-hydroxyindole derivates after administration of L-5-hydroxytryptophan ethyl ester.
    Korf J, Sebens JB, Venema K, van Praag HM.
    Res Commun Chem Pathol Pharmacol; 1976 Sep 19; 15(1):171-82. PubMed ID: 968174
    [Abstract] [Full Text] [Related]

  • 10. Differential effect of carbidopa on the concentration of rat pineal and hypothalamic indoleamines.
    Oxenkrug GF, McIntyre IM, Novak EA, Hryhorczuk LM, Frohman CE.
    J Pineal Res; 1984 Sep 19; 1(4):349-53. PubMed ID: 6085877
    [Abstract] [Full Text] [Related]

  • 11. Human pharmacokinetics of long term 5-hydroxytryptophan combined with decarboxylase inhibitors.
    Magnussen I, Van Woert MH.
    Eur J Clin Pharmacol; 1982 Sep 19; 23(1):81-6. PubMed ID: 6182005
    [Abstract] [Full Text] [Related]

  • 12. L-5-hydroxytryptophan does not stimulate LH secretion directly from the pituitary in patients with gonadotrophin releasing hormone deficiency.
    Lado-Abeal J, Graña M, Rey C, Cabezas-Cerrato J.
    Clin Endocrinol (Oxf); 1998 Aug 19; 49(2):203-7. PubMed ID: 9828908
    [Abstract] [Full Text] [Related]

  • 13. An unexpected effect of L-5 hydroxytryptophan-ethyl-ester combined with a peripheral decarboxylase inhibitor on human serum prolactin.
    van Praag HM, Korf J, Lequin RM.
    Psychopharmacol Commun; 1976 Aug 19; 2(5-6):369-78. PubMed ID: 1088302
    [Abstract] [Full Text] [Related]

  • 14. Formation of serotonin by rat kidneys in vivo.
    Stier CT, Itskovitz HD.
    Proc Soc Exp Biol Med; 1985 Dec 19; 180(3):550-7. PubMed ID: 3878522
    [Abstract] [Full Text] [Related]

  • 15. The origin of blood 5-hydroxyindoleacetic acid following L-hydrazine-alpha-methyldopa (MK-486).
    Warsh JJ, Stancer HC.
    Eur J Pharmacol; 1975 May 19; 32(1):128-32. PubMed ID: 1080116
    [Abstract] [Full Text] [Related]

  • 16. The origin of blood k-hydroxyindoleacetic acid following L-hydrazino-alpha-methyldopa (MK-486).
    Warsh JJ, Stancer HC.
    Eur J Pharmacol; 1975 May 19; 32(1):128-32. PubMed ID: 1080115
    [Abstract] [Full Text] [Related]

  • 17. Aromatic L-amino acid decarboxylase activity in the rat median eminence, neurointermediate lobe and anterior lobe of the pituitary. Physiological and pharmacological implications for pituitary regulation.
    Johnston CA, Spinedi E, Negro-Vilar A.
    Neuroendocrinology; 1984 Jul 19; 39(1):54-9. PubMed ID: 6205316
    [Abstract] [Full Text] [Related]

  • 18. Brain and peripheral metabolism of 5-hydroxytryptophan-14C following peripheral decarboxylase inhibition.
    Warsh JJ, Stancer HC.
    J Pharmacol Exp Ther; 1976 Jun 19; 197(3):545-55. PubMed ID: 1084420
    [Abstract] [Full Text] [Related]

  • 19. Prolactin release after 5-hydroxytryptophan treatment requires an intact neurointermediate pituitary lobe.
    Johnston CA, Fagin KD, Alper RH, Negro-Vilar A.
    Endocrinology; 1986 Feb 19; 118(2):805-10. PubMed ID: 2417827
    [Abstract] [Full Text] [Related]

  • 20. Measurement of 5-hydroxyindole compounds during L-5-HTP treatment in depressed patients.
    Takahashi S, Takahashi R, Masumura I, Miike A.
    Folia Psychiatr Neurol Jpn; 1976 Feb 19; 30(4):463-73. PubMed ID: 1088138
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.